Hemosonics


Launched:

2010

Management:

Timothy Fischer

Duke Inventor(s):

Gregg Trahey, William Walker

HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra™, that provides actionable information to guide the management of critical bleeding and clotting. Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings.

Transforming The Management Of Critical Bleeding and Clotting

Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted transfusion of blood products.

We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely information on coagulation status at the point of care. We are developing a next-generation near patient diagnostic platform that provides actionable information to guide the management of critical bleeding. This enables clinicians to choose the right treatment in the right time frame, dramatically improving outcomes. Our innovative in vitro diagnostic platform characterizes hemostasis – the balance between bleeding and clotting ­– in a variety of acute care clinical settings.